December 21, 2016
Bristol-Myers Squibb Company and Calithera Biosciences, Inc., a clinical stage biotechnology company focused on discovering and developing new small molecule drugs directed against tumor metabolism and tumor immunology targets for treating cancer, have announced a clinical trial collaboration to evaluate the Opdivo of Bristol-Myers Squibb in combination with CB-839 of Calithera in patients with clear cell renal cell carcinoma (ccRCC). CB-839 is an orally administered glutaminase inhibitor currently in Phase 1/2 clinical studies.
Fouad Namouni, M.D., senior vice president, head of Oncology Development, Bristol-Myers Squibb, said: “Influencing the tumor microenvironment remains a key area of focus of research, and we are excited to explore the potential benefits of Opdivo plus CB-839 in an effort to advance new combination therapies for difficult to treat cancers.”
“The combination with Opdivo follows our strategy to combine CB-839 with therapies to improve outcomes for RCC patients. We believe that by blocking glutamine consumption in tumors, and redirecting this key nutrient for cell growth and proliferation to T-cells, CB-839 could enhance the effects of Opdivo. With support from Bristol-Myers Squibb, Calithera is excited to advance this combination into the Phase 2 portion of CX-839-004, our ongoing study in ccRCC patients,” said Susan Molineaux, CEO of Calithera Biosciences.BMS and Calithera Announce Clinical Collaboration to Evaluate nivolumab in combination with CB-839 for Renal Cell Carcinomalast edit: 2017-01-05T16:23:09+00:00da